Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6872400 | 1.00 | L3MBTL1 (0.43) | L3MBTL1LDHAAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7015545 | 1.00 | L3MBTL1 (0.43) | L3MBTL1LDHAAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL11507244 | 0.78 | NPSR1 (0.51) | L3MBTL1LDHAAKR1C3AKR1C2PTGS1 | |
| SCHEMBL12493635 | 0.72 | ALDH1A1 (0.48) | L3MBTL1GABBR2GABBR1NPSR1CA1 | |
| SCHEMBL11507071 | 0.72 | ALOX15 (0.49) | L3MBTL1GABBR2GABBR1NPSR1HPGD | |
| SCHEMBL20301957 | 0.72 | LDHA (0.46) | L3MBTL1LDHAAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL28558539 | 0.71 | LDHA (0.53) | LDHA | |
| SCHEMBL29226421 | 0.70 | ALDH1A1 (0.46) | LDHACA1CA2AOC3 | |
| SCHEMBL29226417 | 0.70 | ALDH1A1 (0.46) | LDHACA1CA2AOC3 | |
| SCHEMBL5824700 | 0.70 | AOC3 (0.50) | L3MBTL1GABBR2GABBR1NPSR1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881839-B2 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-04-19 | — | — | US | claimed |
| US-20040127704-A1 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-07-01 | — | — | US | claimed |
| US-6881839-B2 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-04-19 | — | — | US | disclosed |
| WO-2004058734-A1 | PROCESS FOR PREPARING DILTIAZEM USING A HETEROGENEOUS TRIFUNCTIONAL CATALYST | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-07-15 | — | — | WO | disclosed |
| US-20040127704-A1 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127704-A1 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | CYP2W1, INMT, TST | L3MBTL1 4178/4885LDHA 1660/4885AKR1C3 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.